2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatmentCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront costReal-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvivalOral cancer drug repositories: Challenges and solutions.
Sharath M, Huntington S, Halene S, Abdelghany O. Oral cancer drug repositories: Challenges and solutions. Journal Of Clinical Oncology 2024, 42: 11063-11063. DOI: 10.1200/jco.2024.42.16_suppl.11063.Peer-Reviewed Original ResearchCancer medicationsOral cancer medicationsLife saving treatmentOral cancer drugsTransfer of drugsDose modificationUnused pillsDrug repositoryState-level programsOral chemotherapyFrequent drug shortagesFederal fundingPatientsNational levelOncology drugsDonation ratesInterstate transferLawDrug recyclingCancer drugsDrugMedicationOut-of-pocket costsInsurance coverageImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2023
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma. Future Oncology 2023, 20: 317-328. PMID: 38050764, DOI: 10.2217/fon-2023-0191.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaReal-world treatment patternsLarge B-cell lymphomaB-cell lymphomaTreatment patternsMedicare beneficiariesFirst-line treatmentFront-line treatmentHealthcare resource useHealth resource useElderly Medicare beneficiariesUnmet need existsOverall survivalR-CHOPMedicare patientsLater linesOlder adultsTreatmentPatientsLymphomaNeed existsSurvivalTwo-thirdsResource useSame periodPeripheral Blasts in a Patient Receiving Chemotherapy
Kshattry S, Parker T, Huntington S. Peripheral Blasts in a Patient Receiving Chemotherapy. JAMA 2023, 330: 1581-1582. PMID: 37801303, DOI: 10.1001/jama.2023.17117.Peer-Reviewed Original ResearchIbrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2286-2295. PMID: 37870435, DOI: 10.1080/10428194.2023.2256911.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaIbrutinib discontinuationLymphocytic leukemiaHalf of patientsMonths of initiationElderly Medicare beneficiariesLarge unmet needPart D low-income subsidyLow-income subsidyCardiovascular comorbiditiesElderly patientsReal-world practiceIbrutinib treatmentLymphocytic lymphomaAdvanced ageClinical trialsMedical CenterMedicare claimsDiscontinuationHigh riskMedicare beneficiariesUnmet needPatientsLeukemiaTwo-thirdsReal-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaReal-world adherenceRefractory chronic lymphocytic leukemiaTyrosine kinase inhibitorsLymphocytic leukemiaB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsNovel oral agentsClinical trial dataOral agentsClinical characteristicsElderly patientsTreatment landscapeTreatment initiationReal-world findingsHigh adherenceMedicare beneficiariesLower discontinuationTrial dataDiscontinuationPatientsOlder adultsKinase inhibitorsAdherenceLeukemiaP1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING
Garg M, Puckett J, Kamal‐Bahl S, Raut M, Ryland K, Chakraborty S, Doshi J, Huntington S. P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING. HemaSphere 2023, 7: e7912542. PMCID: PMC10429930, DOI: 10.1097/01.hs9.0000973652.79125.42.Peer-Reviewed Original ResearchAssessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leukemia & Lymphoma 2023, 64: 1752-1770. PMID: 37497877, DOI: 10.1080/10428194.2023.2234525.Peer-Reviewed Original ResearchConceptsHealthcare resource utilizationMantle cell lymphomaElderly patientsTreatment patternsCell lymphomaUnmet needLater linesNational Medicare claimsHalf of patientsHealth care utilizationElderly Medicare beneficiariesLarge unmet needReal-world outcomesCause hospitalizationOverall survivalCare utilizationHospitalization ratesNovel therapiesMedicare claimsL regimenHealthcare costsMedicare beneficiariesL treatmentPatientsLymphomaTreatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original Research
2022
Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia
Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia. Blood 2022, 140: 319-321. DOI: 10.1182/blood-2022-158465.Peer-Reviewed Original ResearchPerceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525)
Odejide O, Huntington S, Hurley S, Kaufman R, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525). Journal Of Pain And Symptom Management 2022, 63: 1111-1112. DOI: 10.1016/j.jpainsymman.2022.04.091.Peer-Reviewed Original ResearchHospice servicesBlood cancersHospice useHematologic malignanciesUtility scoresAdvanced hematologic malignanciesBlood cancer patientsCaregiver focus groupsAdult patientsBlood transfusionMedian ageCancer CenterCancer patientsAcute leukemiaHospice modelValue patientsMedical appointmentsCancer placesPatientsRespite careWeb-based surveyTransfusionCancerCognitive debriefingMalignancy
2021
Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020
Huntington SF, Ingham MP, Okonkwo L, Singh A, Wang R, Ammann EM. Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020. Leukemia & Lymphoma 2021, 63: 1180-1190. PMID: 34913805, DOI: 10.1080/10428194.2021.2012666.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaOverall survivalMedicare Advantage beneficiariesMyeloid leukemiaEconomic burdenFirst-line treatment choiceMedian overall survivalMedicare Advantage patientsUnmet medical needSupportive careAgent monotherapyAML patientsClinical outcomesContemporary cohortTreatment patternsAdvantage patientsTreatment choicePatient managementMedical needHealthcare expendituresPatientsOlder adultsLeukemiaPresent studySurvivalCost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2021, 62: 2777-2784. PMID: 34151696, DOI: 10.1080/10428194.2021.1933477.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioRefractory multiple myelomaMultiple myelomaWeekly selinexorR Multiple MyelomaProgression-free survivalUS payer perspectiveCost-effectiveness ratioWeekly bortezomibTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessBortezomibIncremental costMyelomaDexamethasoneSelinexorQALYVDPatientsClinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemiaCost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyeloma
2020
Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsMultiple myelomaTreatment optionsPhase II/IIICumulative ranking (SUCRA) probabilitiesFirst-line treatmentHematopoietic cell transplantationTerms of efficacyRandom-effects modelEfficacious regimensFrailty biomarkersFrontline regimensThalidomide maintenanceEffective regimensGeriatric assessmentLine treatmentTreatment regimensCell transplantationMeeting libraryIndividual patientsToxicity profileRegimensPatientsSystematic reviewRanking probabilityClinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differences